Skip to main content

Advertisement

Log in

Clinicopathological and Molecular Study of Triple-Negative Breast Cancer in Algerian Patients

Pathology & Oncology Research

Abstract

Triple-negative breast cancer (TNBC) is associated with aggressive tumor behavior, poor prognosis and BRCA1 mutations. There are limited data regarding TNBC among Algerian women. In this study, we sought to determine clinical and tumor characteristics associated with TNBC. We also screened for the prevalence of BRCA1 mutations in unselected cohort of TNBC patients. Clinical and tumor characteristics data of 877 breast cancer patients diagnosed between 2011 and 2015, were collected from cancer registry of public hospital of Rouiba. Patients were divided in two groups: those with TNBC and those with other breast cancer subtypes. Differences between the two groups with regard to clinical and tumor characteristics were compared using Fisher’s exact test. BRCA1 mutations analysis was performed in unselected cohort of 103 women with TNBC, including all exons where a mutation was previously found in Algerian population (exons 2, 3, 5, 11). The median age at diagnosis for TNBC and non-TNBC patients was 47.4 years and 49.4 years, respectively. The proportion of TNBC was 19.95%. Our data showed significant differences in menopausal status, TNM stage, histological type, tumor histological grade, Ki67 expression and family history of breast cancer between TNBC and non-TNBC patients. Four distinct deleterious mutations in BRCA1 gene were detected in eight young TNBC patients. TNBC is associated with young age, poor histopathological characteristics and family history of breast cancer. BRCA1 mutations have been detected in young TNBC patients. TNBC phenotype should be added as criterion to screen for BRCA1 mutations in Algerian women.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Abbreviations

Array–CGH:

Array Comparative Genomic Hybridisation

ER:

Estrogen Receptor

HER2:

Human Epidermal growth factor Receptor 2,

Ki67:

Antigen Ki67

IDC:

Invasive Ductal Carcinoma

IHC:

Immunohistochemistry

ILC:

Invasive Lobular Carcinoma

IPC:

Infiltrating Papillary Carcinoma

LGR:

Large Genomic Rearrangement

MC:

Mixed Carcinoma (invasive ductal and invasive lobular)

MLPA:

Multiplex Ligation Probe Amplification

NGS:

Next Generation Sequencing

PR:

Progesterone Receptor

References

  1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008 GLOBOCAN. Int J Cancer 127:2893–2917

    Article  CAS  PubMed  Google Scholar 

  2. GLOBOCAN: Breast cancer incidence and mortality worldwide (2012) International agency for research on cancer; 2012. http://globocan.iarc.fr/old/FactSheets/cancers/breast-new.asp. Accessed 21 March 2016

  3. Podo F, Buydens LMC, Degani H et al (2010) Triple_negative breast cancer: present challenges and new perspectives. Mol Oncol 4:209–229

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Carey L, Winer E, Viale G, Cameron D, Gianni L (2010) Triple negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol 7:683–692

    Article  PubMed  Google Scholar 

  5. Dent R, Trudeau M, Pritchard KI et al (2007) Triple negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13:4429–4434

    Article  PubMed  Google Scholar 

  6. Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA 295:2492–2502

    Article  CAS  PubMed  Google Scholar 

  7. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population- based study from the California cancer. Registry 109:1721–1728

    Google Scholar 

  8. Huo D, Ikpatt F, Khramtsov A et al (2009) Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple negative breast cancer. J Clin Oncol 27:4515–4521

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Stark A, Kleer CG, Martin I et al (2010) African ancestry and higher prevalence of triple negative breast cancer: findings from an international study. Cancer 116:4926–4932

    Article  PubMed  PubMed Central  Google Scholar 

  10. Amirikia KC, Mills P, Bush J, Newman LA (2011) Higher population-based incidence rates of triple-negative breast cancer among young African-American women: implications for breast cancer screening recommendations. Cancer 117:2747–2753

    Article  PubMed  PubMed Central  Google Scholar 

  11. Ly M, Antoine M, Dembélé AK et al (2012) High incidence of triple-negative tumors in sub-Saharan Africa: a prospective study of breast cancer characteristics and risk factors in Malian women seen in a Bamako university hospital. Oncology 83:257–263

    Article  PubMed  Google Scholar 

  12. Su Y, Zheng Y, Zheng W et al (2011) Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population- based cohort study. BMC Cancer 11:292

    Article  PubMed  PubMed Central  Google Scholar 

  13. Banegas MP, Tao L, Altekruse S et al (2014) Heterogeneity of breast cancer sub-types and survival among Hispanic women with invasive breast cancer in California. Breast Cancer Res Treat 144:625–634

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Singh M, Ding Y, Zhang LY et al (2014) Distinct breast cancer subtypes in women with early- onset disease across races. Am J Cancer Res 4:337–352

    PubMed  PubMed Central  Google Scholar 

  15. Fourati A, Boussen H, El May MV et al (2014) Descriptive analysis of molecular subtypes in Tunisian breast cancer. Asia Pac J Clin Oncol 10:e69–e74

    Article  PubMed  Google Scholar 

  16. Bosch A, Eroles P, Zaragoza R, Vina JR, Lluch A (2010) Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. Cancer Treat Rev 36:206–205

    Article  CAS  PubMed  Google Scholar 

  17. Wong ESY, Shekar S, Chan CHT et al Predictive factors for BRCA1 and BRCA2 genetic testing in an Asian clinic-based population. PLoS ONE 7:e0134408. doi:10.1371/journal.pone.0134408

  18. De Ruitjter TC, Veeck J, Hoon JPJ, Van Engeland M, Tjan-Heijnen VC (2011) Characteristics of triple-negative breast cancer. J Cancer Res Clin Oncol 137:183–192

    Article  Google Scholar 

  19. Robertson L, Hanson H, Seal S et al (2012) BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years. Br J Cancer 106:1234–1238

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Stevens KN, Vachon CM, Couch FJ (2012) Genetic susceptibility to triple-negative breast cancer. Cancer Res 7:2025–2030

    Google Scholar 

  21. Pern F, Bogdanova N, Schürmann LM et al (2012) Mutation analysis of BRCA1, BRCA2, PALB2 and BRD7 in a hospital based series of German patients with triple-negative breast cancer. PLoS One 7:e47993. doi:10.1371/journal.pone.0047993

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Fong PC, Boss DS, Yap TA et al (2009) Inhibition of poly (ADPribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361:123–134

    Article  CAS  PubMed  Google Scholar 

  23. Tutt A, Robson M, Garber JE et al (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376:235–244

    Article  CAS  PubMed  Google Scholar 

  24. Cherbal F, Bakour R, Adane S, Boualga K (2013) BRCA1 and BRCA2 germline mutation spectrum in hereditary breast/ovarian cancer families from Maghrebian countries. Breast Dis 34:1–8

    Article  Google Scholar 

  25. Sobin LH, Wittekind CH (2002) Breast tumors. In: Sobin LH, Wittekinds CH (eds) Classification of malignant tumors, 6th edn. Wiley-Liss, Geneva, pp 131–142

    Google Scholar 

  26. Pennacchia I, Carbone A, Di Cerbo A, Vecchio FM, Arena V (2015) 2013 ASCO/CAP updated guidelines for human epidermal growth factor receptor 2 testing: impact on routine practice. Breast 24:285e6

    Article  Google Scholar 

  27. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ, Panel members (2011) Strategies for sub- types – dealing with the diversity of breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol 22:1736–1747. doi:10.1093/annonc/mdr304

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thürlimann B, Senn HJ, Panel Members (2015) Tailoring therapies-improving the management of early breast cancer: St Gallen international expert consensus on the primary therapy of early breast cancer 2015. Ann Oncol 26:1533–1546. doi:10.1093/annonc/mdv221

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Cherbal F, Bakour R, Adane S, Boualga K, Benais-Pont G, Maillet P (2010) BRCA1 and BRCA2 germline mutations screening in Algerian breast/ovarian cancer families. Dis Markers 28:377–384

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Rais G, Raissouni S, Aitelhaj M et al (2012) Triple-negative breast cancer in Moroccan women: clinicopathological and therapeutic study at the National Institute of oncology. BMC Womens Health 12:35

    Article  PubMed  PubMed Central  Google Scholar 

  31. Minicozzi P, Bella F, Toss A et al (2013) Relative and disease-free survival for breast cancer in relation to subtype: a population-based study. J Cancer Res Clin Oncol 139:1569–1577

    Article  CAS  PubMed  Google Scholar 

  32. Clarke CA, Keegan TH, Yang J et al (2012) Age-specific incidence of breast cancer subtypes: understanding the black-white crossover. J Natl Cancer Inst 104:1094–1101

    Article  PubMed  PubMed Central  Google Scholar 

  33. Rakha EA, El-Sayed ME, Green AR (2007) Prognostic markers in triple-negative breast cancer. Cancer 109:25–32

    Article  CAS  PubMed  Google Scholar 

  34. Ann J, Kang S, Kwun K (2008) Clinicopathologic characteristics of triple negative breast cancer in early stages. Eur J Cancer Supp 6:183

    Article  Google Scholar 

  35. Qiu J, Xue X, Hu C et al (2016) Comparison of Clinicopathological features and prognosis in triple-negative and non-triple negative breast cancer. J Cancer 7:167–173

    Article  PubMed  PubMed Central  Google Scholar 

  36. Li CY, Zhang S, Zhang XB, Wang P, Hou GF, Zhang J (2013) Clinicopathological and prognostic characteristics of triple-negative breast cancer (TNBC) in Chinese patients: a retrospective study. Asian Pac J Cancer Prev 14:3779–3784

    Article  PubMed  Google Scholar 

  37. Collaborative group on Hormonal factors in Breast Cancer (2012) Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet 360:187–195

    Google Scholar 

  38. Anothaisintawee T, Wiratkapun C, Lerdsitthichai P et al (2013) Risk factors of breast cancer: a systematic revew and meta-analysis. Asia Pac J Public Health 25:368–4943

    Article  PubMed  Google Scholar 

  39. Islami F, Liu Y, Jemal A et al (2015) Breastfeeding and breast cancer risk by receptor status- a systematic review and meta-analysis. Ann Oncol 26:2398–2407

    CAS  PubMed  PubMed Central  Google Scholar 

  40. Shinde SS, Forman MR, Kuerer HM et al (2010) Higher parity and shorter breast feeding duration: association with triple-negative phenotype of breast cancer. Cancer 116:4933–4943

    Article  PubMed  Google Scholar 

  41. Jung SY, Jeong J, Shin SH et al (2010) The invasive lobular carcinoma as a prototype luminal a breast cancer: a retrospective cohort study. BMC Cancer 10:664

    Article  PubMed  PubMed Central  Google Scholar 

  42. Koo JS, Jung WH (2011) Clinicopathlogic and Immunohistochemical characteristics of triple negative invasive lobular carcinoma. Yonsei Med J 52(1):89–97

    Article  PubMed  Google Scholar 

  43. Lee E, McKean-Cowdin R, Ma H et al (2011) Characteristics of triple negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women. J Clin Oncol 29:4373–4380

    Article  PubMed  PubMed Central  Google Scholar 

  44. Wong-Brown MW, Meldrum CJ, Carpenter JE et al (2015) Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer. Breast Cancer Res Treat 50:71–80

    Article  Google Scholar 

  45. Foulkes WD, Metcalfe K, Sun P et al (2004) Estrogen receptor status in BRCA1-BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res 10:2029–2034

  46. Gonzalez-Angulo AM, Timms KM, Liu S et al (2011) Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 17:1082–1089

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Hartman AR, Kaldate RR, Sailer LM et al (2012) Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer. Cancer 118:2787–2795

    Article  CAS  PubMed  Google Scholar 

  48. Rummel S, Varner E, Shriver CD, Ellsworth RE (2013) Evaluation of BRCA1 mutations in an unselected patient population with triple- negative breast cancer. Breast Cancer Res Treat 137:119–125

    Article  PubMed  Google Scholar 

  49. Couch FJ, Hart SN, Sharma P et al (2014) Inherited mutations in 17 breast cancer susceptibility genes among a large triple negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol. doi:10.1200/JCO.2014.57.1414

    PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We deeply thank the patients and their families for their participation. This study was supported by the Algerian National Research Program FNRSDT. FC would like to thank Dr. Philippe Maillet (Ornex, France), Prof. Kada Boualga (Anti-Cancer Center, Blida, Algeria), Daoud Cherbal and Romaissa Cherbal for their support to the research program on hereditary cancers in Algerian population.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Farid Cherbal.

Ethics declarations

Conflicts of Interest

The authors declare non conflict of interest.

Ethical Approval

All TNBC patients tested for BRCA1 germline mutations signed written informed consent. The study was approved by the institutional review boards and ethical approval was obtained from appropriate institutions (USTHB, EPH Rouiba, FNRSDT and CNEPRU Project N° D01N01UN160420130007, 103 participants, start date: 3/07/2013, end date: 12/16/2015).

Informed Consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gaceb, H., Cherbal, F., Bakour, R. et al. Clinicopathological and Molecular Study of Triple-Negative Breast Cancer in Algerian Patients. Pathol. Oncol. Res. 24, 297–308 (2018). https://doi.org/10.1007/s12253-017-0242-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-017-0242-2

Keywords

Navigation